NEJM February 2026 Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents

This Week In Medicine · Feb 12, 2026 · 16m

This clinical study evaluated whether patients with atrial fibrillation who have lived with a drug-eluting stent for at least one year should take a single anticoagulant or a combination of an anticoagulant and an antiplatelet drug. By tracking the occurrence of major health complications and bleeding over a twelve-month period, researchers discovered that those using only a non-vitamin K antagonist oral anticoagulant (NOAC) experienced significantly fewer adverse clinical events. Most notably, the data revealed that monotherapy substantially reduced the risk of bleeding without compromising…